Showing session: reset
Opening Plenary: The Genome and Beyond
- Sort by:
- Browse by:
- Free
- podium video
- slides video
- audio + slides
- All slides included
Insights from cancer genomes into the mutational processes underlying cancer development
Michael R. Stratton
Wellcome Trust Sanger Inst., Cambridge, United Kingdom
- Free
- podium video
- slides video
- audio + slides
- All slides included
Engineering the cancer genome
Tyler Jacks
David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, United States
- Free
- podium video
- slides video
- audio + slides
- All slides included
Above the genome: The epigenome and its biology and translational potential
Stephen B. Baylin
Johns Hopkins University School of Medicine, Baltimore, MD, United States
- Free
- podium video
- slides video
- audio + slides
- All slides included
Using genomics to personalize cancer immunotherapy
Robert D. Schreiber
Washington University School of Medicine, St. Louis, MO, United States
- Free
- podium video
- slides video
- audio + slides
- All slides included
Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, United States
- Free
- podium video
- slides video
- audio + slides
- All slides included
Discussant: Phase III study of pembrolizumab (MK-3475) versus ipilimumab (Ribaset al.)
Jedd D. Wolchok
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Free
- podium video
- slides video
- audio + slides
- All slides included
Dual targeting of BCR-ABL with ABL001: A novel potent allosteric ABL kinase inhibitor in combination with nilotinib suppresses the emergence of disease resistance in models of CML
William R. Sellers
Novartis Insts. for BioMedical Research, Cambridge, MA, United States